Pradaxa

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

8 competitors in Male

#DrugCompanyPhaseTrials

1

Sensipar

Amgen

Approved

12

Crestor

AstraZeneca

Phase 1

—3

Pradaxa

Boehringer Ingelheim

Phase 1

—4

Romvimza

DDeciphera Pharmaceuticals, LLC

Phase 1

—5

Pradaxa

Boehringer Ingelheim

Phase 1

46

Chf10196

Chiesi Farmaceutici S.p.A.

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A Phase 1, Open-label, Fixed Sequence Study to Evaluate The Effect of Steady-State Dosing of PF-08049820 on the Single Dose Pharmacokinetics of Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Completed·Pfizer·Phase 1·NCT07190430·16 enrolled

Unspecified3 trials

A Phase 1, Open-label, Fixed-sequence Trial in Healthy Participants to Assess the Drug Interaction Potential of BGB-43395 With A Drug Cocktail Representative for CYP3A4, CYP2C9, P-gp, and BCRP Substrates

Not yet recruiting·BBeOne Medicines·Phase 1·NCT07820891·24 enrolled

An Open-label, Fixed-sequence, Non-randomized, Drug-drug Interaction Study to Evaluate the Effect of CHF10196 on the Pharmacokinetics of Dabigatran (P-gp Substrate) and Rosuvastatin (BCRP Substrate) in Healthy Male Participants.

Not yet recruiting·Chiesi Farmaceutici S.p.A.·Phase 1·NCT07744386·24 enrolled

A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986533 in Healthy Participants, an Open-label Assessment of Food and pH Effects on the Relative Bioavailability of BMS-986533, and an Open-label Study to Evaluate P-gp- and BCRP-mediated Drug-Drug Interaction Potential of BMS-986533 in Healthy Participants

Recruiting·Bristol-Myers Squibb·Phase 1·NCT07629999·136 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News